Abstract:Abstract Background: Pexidartinib is a novel, orally active, small-molecule kinase inhibitor that selectively targets the colony-stimulating factor-1 receptor (CSF1R), as well as the receptors c-kit and oncogenic Flt3. Based on these targets, pexidartinib may inhibit tumor growth directly by blocking oncogenic drivers such as CSF-1, c-kit, and Flt3, or indirectly by modulating the tumor microenvironment and interactions between stromal cells and tumors. This first study in Asia evaluated the safety, tolerability, and pharmacokinetic (PK) profile in an Asian population. Methods: This phase 1 non-randomized, open-label, multiple-dose study evaluated the safety and tolerability of pexidartinib in Asian patients with advanced solid tumors. This dose-escalation study employed a 3+3 design and included 2 dose levels. Patients at dose level 1 received 600 mg/day and patients at dose level 2 received 1000 mg/day for the first 2 weeks followed by 800 mg/day thereafter. Patients still receiving treatment after four 28-day cycles were eligible to continue pexidartinib in an extension phase. Treatment continued until disease progression, unacceptable toxicity, or withdrawal of consent. Study objectives included assessment of pexidartinib safety and tolerability, PK, and pharmacodynamic effects on circulating CSF-1 and adiponectin, as well as determination of the maximum tolerated and recommended phase 2 doses (MTD and RP2D). Results: Eleven patients (6 males and 5 females, median age 64, range 23-82) were treated with pexidartinib in the dose-escalation phase. Preliminary PK data indicate that exposure (Cmax and AUC0-8h) increased proportionally with dose and the plasma concentration level increased after multiple doses. CSF-1 and adiponectin plasma concentrations increased after administration of pexidartinib. Grade ≥3 adverse events (AEs) observed were increased alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, and bilirubin, as well as anemia and lower back pain. No patients experienced dose-limiting toxicities, and the MTD was determined to be 1000 mg/day. At the time of this analysis, 7 patients had experienced disease progression, 3 patients had withdrawn from the study, and 1 patient with tenosynovial giant cell tumor continued to receive pexidartinib for more than 341 days. Conclusions: Pexidartinib was determined to be safe and tolerable at the 1000 mg/day dose for Asian patients, and the most common treatment-related AEs were elevated liver enzyme levels. Pexidartinib demonstrated clinical activity in a patient with tenosynovial giant cell tumor, and is being evaluated in a phase 3 study for patients with tenosynovial giant cell tumors in Western countries (NCT02371369). Citation Format: Chia-Chi Lin, Jih-Hsiang Lee, Chih-Hung Hsu, Wei-Wu Chen, Yu-Hsin Yen, Chih-Hsin Yang, Ling Zhang, Shun-ichi Sasaki, Lillian Chiu, Ann-Lii Cheng. A phase 1 study of single-agent pexidartinib in Asian patients with advanced solid tumors (NCT02734433) [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A080.

Perhexiline maleate in the treatment of fibrodysplasia ossificans progressiva: an open-labeled clinical trial

Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva

Towards targeting overactive BMP signaling in Fibrodysplasia Ossificans Progressiva

Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva.

[18F]NaF PET/CT as a Marker for Fibrodysplasia Ossificans Progressiva: From Molecular Mechanisms to Clinical Applications in Bone Disorders

Current and emerging treatment modalities for fibrodysplasia ossificans progressiva

iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva

Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial

Cellular and Molecular Mechanisms of Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva

Oxidative phosphorylation is a pivotal therapeutic target of fibrodysplasia ossificans progressiva

PI3Kα inhibition blocks osteochondroprogenitor specification and the hyper-inflammatory response to prevent heterotopic ossification

[Progress on Prevention and Treatment of Heterotopic Ossification].

Immunologic Aspects in Fibrodysplasia Ossificans Progressiva

Effects of Sequential Treatment with Intermittent Parathyroid Hormone and Zoledronic Acid on Particle-Induced Implant Loosening: Evidence from a Rat Model

An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva

Abstract A080: A Phase 1 Study of Single-Agent Pexidartinib in Asian Patients with Advanced Solid Tumors (NCT02734433)

Local Influence of High Molecular Polyethylene Particles on Heterotopic Ossification

Oral supplementation of inorganic pyrophosphate in pseudoxanthoma elasticum

Performance of simplified methods for quantification of [18F]NaF uptake in fibrodysplasia ossificans progressiva

Periosteal expansion osteogenesis using a tubular dynamic frame device: An experimental study in rats

MMP-9 deficiency confers resilience in Fibrodysplasia Ossificans Progressiva in a man and mice